Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Six and three months ended November 30, 2010 (Fiscal Year 2011)
Business Overview: Biomerica develops, manufactures, and markets medical diagnostic products for the early detection of chronic diseases. Products are sold to clinical laboratories and point-of-care markets (physicians' offices and drugstores) globally. The company maintains manufacturing operations in Irvine, California, and Mexicali, Mexico.
Key Financial Metrics
| Metric | Six Months Ended Nov 30, 2010 | Six Months Ended Nov 30, 2009 | Three Months Ended Nov 30, 2010 | Three Months Ended Nov 30, 2009 |
|---|---|---|---|---|
| Net Sales | $2,338,554 | $2,248,401 | $1,160,842 | $1,099,880 |
| Gross Profit | $689,325 | $592,954 | $300,545 | $216,517 |
| Gross Margin | 29.5% | 26.4% | 25.9% | 19.7% |
| Operating Loss | $(189,845) | $(301,480) | $(177,615) | $(306,199) |
| Net (Loss) Income | $(12,049) | $(297,772) | $137 | $(305,706) |
| Cash and Equivalents (Nov 30, 2010) | $972,097 | |||
| Total Debt (Current + Long-term) | $58,375 | |||
| Working Capital | $3,066,179 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.0% for the six-month period and 5.5% for the quarter compared to the prior year, driven by increased sales of EZ Detect to chain drug stores and food allergy test kits to distributors.
- Profitability Improvement: The company significantly reduced its net loss from $(297,772) to $(12,049) for the six-month period. This improvement was primarily due to a non-recurring research grant of approximately $177,605 recognized in "Other Income."
- Cost Management: Cost of sales as a percentage of sales decreased from 73.6% to 70.5% for the six-month period. Selling, general, and administrative (SG&A) expenses decreased by 7.0% year-over-year, largely because the prior year included approximately $84,000 in non-recurring moving expenses.
- Operating Cash Flow: Operating cash flow turned positive, generating $77,563 compared to a usage of $(26,278) in the prior year, aided by the collection of receivables and utilization of prepaid expenses.
Guidance, Outlook, and Risks
Management Commentary: Management notes that the elimination of the dedicated research department in favor of licensing technology is a current strategy. The company received a grant under the Qualifying Therapeutic Discovery Project program (Section 48D of the Internal Revenue Code), with approximately $140,000 remaining to be received in the future contingent on qualifying expenses.
Risks and Contingencies:
- Concentration Risk: One customer comprised 25.8% of gross receivables as of November 30, 2010, and another comprised 14.8%.
- Regulatory and Market Risks: Risks include fluctuations in operating results, success in raising capital, maintaining NASDAQ listing requirements, and potential delays in regulatory approvals.
- Operational Risks: Dependence on international distributors, raw material availability, and potential disruptions to foreign manufacturing operations in Mexico.
Unusual Items: The significant "Other Income" of $177,605 for the six-month period is non-operating and related to the government research grant mentioned above.
Investor Verification Checklist
- Grant Sustainability: Verify the conditions for receiving the remaining ~$140,000 of the research grant and the likelihood of future similar awards.
- Customer Concentration: Assess the creditworthiness and stability of the two customers representing over 40% of gross receivables.
- Recurring Profitability: Analyze operating income excluding the one-time grant to determine the core business's path to profitability.
- Liquidity Position: Monitor cash burn rates relative to the $972,097 cash balance and the $400,000 line of credit (currently at zero balance).
- Inventory Levels: Review inventory turnover given the increase in raw materials and work-in-progress inventory.